Fri, Nov 20, 2026中文About
Filings today 284 / Covered 15
Source: TDnet timely disclosures
Updated 11/20 20:30M&A / TOB 20 Guidance 7 Buybacks 11 Dividends 4 Capital 12 Earnings 16 People 3

Amvis cuts FY net profit forecast 40.5% to ¥1.25 bln on ¥2.14 bln impairment

Mon, Nov 09, 2026 16:00 JST Amvis Holdings (7071.T) Services 中文

Amvis Holdings (7071) cut its net profit forecast for the fiscal year ended Sept. 30, 2026 by 40.5% to ¥1.25 billion from ¥2.1 billion after booking an impairment loss of ¥2.142 billion.

Revised net profit forecast¥1.25 billion
Impairment loss¥2.142 billion
Revised operating profit forecast¥4.0 billion
Expected gain on share saleapprox. ¥7.9 billion

The impairment covers some of the group's Ishinkan facilities. After reviewing the recoverability of fixed assets, the company wrote down facilities with reduced profitability to their recoverable amounts, booking ¥1.636 billion for facilities in western Japan and ¥506 million for those in eastern Japan. The company said the impairment itself involves no new cash outflow.

ItemPrevious forecastRevised forecastChange
Sales¥51.7 billion¥50.0 billion-3.3%
EBITDA¥7.1 billion¥7.45 billion+4.9%
Operating profit¥3.8 billion¥4.0 billion+5.3%
Recurring profit¥3.3 billion¥4.0 billion+21.2%
Net profit¥2.1 billion¥1.25 billion-40.5%
EPS¥21.53¥12.77-

Sales are expected to come in broadly in line with the previous forecast, while operating and recurring profit will exceed it as the comprehensive medical support business expanded more than expected. Net profit falls short due to the impairment. In the prior year, sales were ¥49.174 billion and net profit ¥3.66 billion.

The western Japan impairment relates to facilities in a business being sold under a plan announced Sept. 28, 2026. Amvis will transfer its Ishinkan business covering 47 facilities, mainly in western Japan, to two wholly owned subsidiaries via a company split and sell all shares of both to NSSK-Altair1. It expects to book a gain on the sale of about ¥7.9 billion in the first quarter of the fiscal year ending September 2027. The estimate reflects the impairment and is not included in the revised forecast.

An extraordinary shareholders' meeting is scheduled for Nov. 13, 2026, and the sale is set for Nov. 16, subject to approval and other conditions. The fiscal 2027 forecast, including the gain and deconsolidation effects, will be released with earnings on Nov. 13.


Original filings
Related